ClinicalTrials.gg
CompletedNCT07421778Updated Oct 6, 2026

A Multiple Ascending Dose Study Evaluating the Safety and Tolerability of a Novel Formulation of QRL-101 in Healthy Participants

A Phase 1 interventional study of QRL-101 and Placebo in Healthy Participant Study, sponsored by QurAlis Corporation. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by QurAlis Corporation · Phase 1, Interventional, and Treatment

Updated Oct 6, 2026Now CompletedEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

QRL-101-08 is a multiple ascending dose (MAD) study to evaluate the safety, tolerability, and pharmacokinetics (PK) of a novel formulation of QRL-101 in healthy participants.

Read the detailed description

Phase 1, single-site, multiple dose study to evaluate the safety, tolerability, and PK of a novel formulation of QRL-101 in healthy participants. Up to 4 cohorts of 12 participants each, randomized 9:3 (QRL-101:placebo) will be tested. The approximate total duration of study participation for each participant may be up to 59 days.

02

Conditions studied

  • Healthy Participant Study
03

In context

Lead sponsor

QurAlis Corporation is the lead sponsor of 7 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 to 65 years of age inclusive at the time of signing the .
  2. Clinical chemistry laboratory values within acceptable range for the population, as per investigator judgment.
  3. of 18 to 32 kg/m2 (inclusive).
  4. Willing and able to practice effective .

Exclusion criteria

Exclusion Criteria:

  1. Currently enrolled in any other clinical trial involving a study drug or off-label use of a drug or device, or any other type of medical research judged not to be scientifically or medically compatible with this study.
  2. Any participant in >4 studies a year and/or has participated in a clinical trial within 1 month of the expected dosing date.
  3. History or presence of medical illness including, but not limited to, any cardiovascular, hepatic, respiratory, hematological, endocrine, psychiatric, or neurological disease, convulsions, or any laboratory abnormality that, in the judgment of the investigator, indicate a medical problem that would preclude study participation.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    QRL-101

    Drug: QRL-101

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Multiple-ascending doses of QRL-101 will be orally administered to healthy participants.

  • DrugPlacebo

    Multiple-ascending doses of comparator placebo will be administered orally to healthy participants.

06

What researchers measure

Primary outcomes

  1. Safety and tolerability

    Number of participants with one or more treatment emergent adverse events and serious adverse events. A summary of treatment emergent adverse events (AEs), serious adverse events (SAEs), and other non-serious adverse events, regardless of causality, will be reported in the Reported Adverse Events module.

    Time frame: Baseline through Follow up (Day 29)

Secondary outcomes

  1. Pharmacokinetics (plasma): Area under the concentration time curve during the dosing interval (AUCτ) of QRL-101

    Area under the concentration time curve during the dosing interval (AUCτ) of QRL-101

    Time frame: Time Frame: Baseline through Follow up (Day 29)

  2. Pharmacokinetics (plasma): Maximum observed concentration of QRL-101

    Maximum observed concentration (Cmax) of QRL-101

    Time frame: Baseline through Follow up (Day 29)

  3. Pharmacokinetics (plasma): Time of maximum concentration of QRL-101

    Time of maximum concentration (Tmax) of QRL-101

    Time frame: Baseline through Follow up (Day 29)

  4. Pharmacokinetics (plasma): Concentration of QRL-101 before the next dose

    Concentration of QRL-101 reached by a drug immediately before the next dose

    Time frame: Baseline through Follow up (Day 29)

  5. Pharmacokinetics (plasma): Terminal elimination half-life of QRL-101

    Terminal elimination half-life of QRL-101

    Time frame: Baseline through Follow up (Day 29)

  6. Pharmacokinetics (plasma): Area under the concentration time curve during the dosing interval (AUCτ) of QRL-101 major metabolites

    Area under the concentration time curve during the dosing interval (AUCτ) of QRL-101 major metabolites

    Time frame: Baseline through Follow up (Day 29)

  7. Pharmacokinetics (plasma): Maximum observed concentration of QRL-101 major metabolites

    Maximum observed concentration (Cmax) of QRL-101 major metabolites

    Time frame: Baseline through Follow up (Day 29)

  8. Pharmacokinetics (plasma): Time of maximum concentration of QRL-101 major metabolites

    Time of maximum concentration (Tmax) of QRL-101 major metabolites

    Time frame: Baseline through Follow up (Day 29)

  9. Pharmacokinetics (plasma): Concentration of QRL-101 major metabolites before the next dose

    Concentration of QRL-101 major metabolites reached by a drug immediately before the next dose

    Time frame: Baseline through Follow up (Day 29)

  10. Pharmacokinetics (plasma): Terminal elimination half-life of QRL-101 major metabolites

    Terminal elimination half-life of QRL-101 major metabolites

    Time frame: Baseline through Follow up (Day 29)

07

Study locations

1 site
  • ICON plc.
    Groningen, 9728 NZ, Netherlands
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2026 to primary completion in Aug 2026, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2026
First posted
Feb 19, 2026
StartActual
Feb 2, 2026
Primary completionActual
Aug 31, 2026
CompletionActual
Aug 31, 2026
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Active, not recruiting→Completed
    + 3 other changes: identifiers, verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07421778
Lead sponsor
QurAlis Corporation
Responsible party
Sponsor
First posted
Feb 19, 2026
Start date
Feb 2, 2026
Primary completion
Aug 31, 2026
Completion
Aug 31, 2026
Last update
Oct 6, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: QRL-101

Start the discussion